Article Versions Notes

Meijer TG, Martens JWM, Prager-van der Smissen WJC, Verkaik NS, Beaufort CM, van Herk S, Robert-Finestra T, Hoogenboezem RM, Ruigrok-Ritstier K, Paul MW, et al. Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient. Cancers. 2024; 16(4):741. https://doi.org/10.3390/cancers16040741

Meijer, Titia G., John W. M. Martens, Wendy J. C. Prager-van der Smissen, Nicole S. Verkaik, Corine M. Beaufort, Stanley van Herk, Teresa Robert-Finestra, Remco M. Hoogenboezem, Kirsten Ruigrok-Ritstier, Maarten W. Paul, and et al. 2024. "Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient" Cancers 16, no. 4: 741. https://doi.org/10.3390/cancers16040741

Meijer, T. G., Martens, J. W. M., Prager-van der Smissen, W. J. C., Verkaik, N. S., Beaufort, C. M., van Herk, S., Robert-Finestra, T., Hoogenboezem, R. M., Ruigrok-Ritstier, K., Paul, M. W., Gribnau, J., Bindels, E. M. J., Kanaar, R., Jager, A., van Gent, D. C., & Hollestelle, A. (2024). Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient. Cancers, 16(4), 741. https://doi.org/10.3390/cancers16040741